Publications by authors named "L Martinez-Costa"
The leading cause of blindness due to non-infectious uveitis is cystoid macular edema (CME). Behçet's disease (BD) is one of the most commonly conditions related to CME. To compare the effectiveness and safety of adalimumab (ADA), infliximab (IFX) and certolizumab (CZP) in refractory CME due to BD.
View Article and Find Full Text PDFIntroduction: This was a multicenter, prospective, longitudinal, observational study involving eight Spanish tertiary hospitals to determine the interobserver reliability of an uveitis disease activity index, (UVEDAI) and assess its sensitivity to change in patients with receiving pharmacologic treatment.
Methods: Patients aged ≥ 18 years diagnosed with active noninfectious uveitis were included. A complete baseline assessment was performed by two ophthalmologists who determined ocular inflammatory activity using the UVEDAI index independently of each other.
Introduction: Uveitis is the inflammation of the middle layer of the eye, the uvea, and is a major cause of blindness. None of the instruments used in clinical practice are, in themselves, sufficient to evaluate the course of uveitis. Therefore, it is necessary to develop instruments enabling standardized measurement of inflammatory activity.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the effectiveness of TNF inhibitors (adalimumab and infliximab) versus tocilizumab in treating refractory cystoid macular edema associated with Behçet’s disease.
- A multicenter analysis included 49 patients with cystoid macular edema who had already undergone other treatments; they were tracked for changes in macular thickness, visual acuity, and inflammation over four years.
- Results showed that all treatment options led to improvements in macular thickness and visual acuity, with tocilizumab still being effective for patients who did not respond to TNF inhibitors.